TFF Pharmaceuticals (NASDAQ:TFFP) Stock, Quote.Headers.trade-ideas

TFF Pharmaceuticals

TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ARRY

BLUE

CVAC

IVVD

LYFT

QURE

SFWL

TFFP

VTNR

U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday.

Shares of bluebird bio, Inc.  (NASDAQ: BLUE) shares fell sharply during Tuesday’s session after the company announced a proposed public offering of $150 million of common stock.

Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday

AAMC

AKTX

AREN

CALT

CELL

CLEU

CSSE

DCTH

DSGN

EAST

FTCH

FWAC

FXLV

GETY

GLTO

GMVD

GROV

HCTI

HRYU

IONM

MGOL

NDRA

NOGN

NVOS

ONON

OPRX

PBTS

PHVS

PSFE

PTRA

RGTI

SLGC

SYTA

TAYD

TBLT

TCRT

TLSA

TRKA

TSVT

TTOO

TWOU

WLDS

XWEL

Gainers


	Novo Integrated Sciences, Inc.  (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project.


Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Pre-Market Outlook

APVO

JTAI

SONM

TSHA

Gainers


	Delcath Systems, Inc. (NASDAQ: DCTH) shares surged 57.7% to $4.93 in pre-market trading after the company reported the FDA approval of HEPZATO KIT™ for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma.


Why Delcath Systems Shares Are Trading Higher By Around 58%; Here Are 20 Stocks Moving Premarket

TFF Pharmaceuticals Inc

<p>Baird  analyst Eric Coldwell   maintains Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) with a Outperform and lowers the price target from $430 to $413.</p>


Price Target

Analyst Ratings

MEDP

Baird Maintains Outperform on Medpace Hldgs, Lowers Price Target to $413

SLDP

Solid Power Says It Is Selected By U.S. Department Of Energy For Up To $50M Award Negotiation For Continuous Production Of Sulfide-based Solid Electrolyte Materials For Advanced All-solid-state Batteries

<p>Baird  analyst Eric Coldwell   maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Outperform and raises the price target from $278 to $282.</p>


Laboratory Corporation Of America Holdings

Baird Maintains Outperform on Labcorp Holdings, Raises Price Target to $282

VinFast Auto Q2 EPS $(0.33) Compared With $(0.24) YoY, Sales Of $357M Rises From $328M YoY

MRNA

CHMP Gave Positive Opinions To Update The Composition Of The Moderna's MRNA Vaccine Spikevax1, To Target SARS-COV-2 JN.1 Variant Of The Virus That Causes Covid-19

<p>Baird  analyst Eric Coldwell   maintains IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) with a Neutral and raises the price target from $251 to $256.</p>


Baird Maintains Neutral on IQVIA Hldgs, Raises Price Target to $256

ABBV

CHMP Recommended Granting Marketing Authorization For Elahere For The Treatment Of Adults With Ovarian Cancer, Fallopian Tube Cancer, Or Primary Peritoneal Cancer

<p>Baird  analyst Eric Coldwell   maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and lowers the price target from $368 to $340.</p>


ICLR

Baird Maintains Outperform on Icon, Lowers Price Target to $340

<p><strong>Macy&#8217;s, Inc.&nbsp;</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) disclosed plans to hire more than 31,500 full- and part-time seasonal positions this upcoming holiday season at its Macy&#8217;s, Bloomingdale&#8217;s, and Bluemercury stores,<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40947705/macys-inc-gears-up-to-hire-for-more-than-31-500-seasonal-positions-to-deliver-joyful-holiday-shopp" rel="noreferrer noopener"> as well as its distribution centers</a>.</p>
<p>Macy&#8217;s offers several convenient hiring experiences for candidates, including an online application process that takes as little as five minutes, with most job offers made within 48 hours.</p>
<p>Additionally, the company is holding four nationwide in-person holiday hiring events at all stores and supply chain locations. Times may vary by location.</p>
<p>Danielle Kirgan, Macy&#8217;s, Inc. chief human resources and corporate affairs officer, said, &#8220;We are excited to add more than 31,500 seasonal positions to help us welcome and serve our customers during the holidays.&#8221;</p>
<p>&#8220;Whether they are looking for extra income for the season or the start of a new career in retail, we offer an unmatched culture, competitive pay and fulfilling career opportunities.&#8221;</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40510353/macys-strong-earnings-tempered-by-weak-sales-but-analysts-see-green-shoots-emerging" rel="noreferrer noopener">Macy&#8217;s Strong Earnings Tempered By Weak Sales, But Analysts See &#8216;Green Shoots&#8217; Emerging</a></strong></p>
<p>Other major U.S. retailers are also stepping up their holiday game. Recently, <strong>Target</strong> also announced its intention to recruit <a target="_blank" href="https://www.benzinga.com/news/24/09/40878577/target-set-to-recruit-100k-seasonal-employees-despite-anticipated-slow-holiday-sales" rel="noreferrer noopener">approximately 100,000 seasonal employees</a>.</p>
<p>Apart from this, this month,&nbsp;<strong>Bath &amp; Body Works</strong> also disclosed plans to hire 30,000 seasonal employees.</p>
<p>Investors can gain exposure to Macy&#8217;s via <strong>Invesco S&amp;P Midcap 400 Pure Value ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFV#NYSE">RFV</a>).</p>
<p><strong>Price Action</strong>: M shares are trading higher by 0.07% at $15.34 premarket at the last check Friday.</p>
<p><em>Photo via Shutterstock</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com//node/40954193" target="_blank" rel="noreferrer noopener">Salesforce CEO Marc Benioff Slams Microsoft&#8217;s Copilot, Compares It To Failed &#8216;Clippy&#8217; Assistant: &#8216;…Like We&#8217;re Selling Science Projects To Companies&#8217;</a></strong></li>
</ul>
<p><strong><em>Disclaimer:</em></strong><em> This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>


Equities

Large Cap

Management

Rydex ETF Trust S&P Midcap 400 Pure Value ETF

Holiday Opportunity: Macy's Plans To Hire 31,500 Seasonal Workers

<p>Baird  analyst Eric Coldwell   maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Neutral and lowers the price target from $191 to $190.</p>


Baird Maintains Neutral on Charles River, Lowers Price Target to $190

<p>Keybanc  analyst Austin Wurschmidt   maintains American Healthcares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) with a Overweight and raises the price target from $27 to $28.</p>


Keybanc Maintains Overweight on American Healthcares, Raises Price Target to $28

<p>Baird  analyst Garrett Holland   maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Outperform and lowers the price target from $340 to $320.</p>


Baird Maintains Outperform on FedEx, Lowers Price Target to $320

Aurora Cannabis Reveals Appointments Of CEO Miguel Martin To Additional Role Of Executive Chairman And Outgoing Chairman Ron Funk As Lead Independent Director; Appointments Follow Unanimous Votes By Aurora's Board And Are Effective Immediately

<p>Under the agreement, Microsoft will purchase energy from the renewed plant as part of its goal to help match the power its data centers in PJM use with carbon-free energy.</p>
<p>Constellation signs its largest-ever power purchase agreement with Microsoft, a deal that will restore TMI Unit 1 to service and keep it online for decades; add approximately 835 megawatts of carbon-free energy to the grid; create 3,400 direct and indirect jobs and deliver more than&nbsp;$3 billion&nbsp;in state and federal taxes</p>


Constellation Signs 20-year Power Purchase Agreement With Microsoft That Will Pave The Way For Launch Of Crane Clean Energy Center And Restart Of Three Mile Island Unit 1

<p>Baird  analyst Robert Mason   initiates coverage on Advanced Energy Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) with a Outperform rating and announces Price Target of $128.</p>


Initiation

AEIS

Baird Initiates Coverage On Advanced Energy Indus with Outperform Rating, Announces Price Target of $128

<p>JMP Securities  analyst Aaron Hecht   maintains American Healthcares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) with a Market Outperform and raises the price target from $18 to $30.</p>


JMP Securities Maintains Market Outperform on American Healthcares, Raises Price Target to $30

VSTO

MNC Capital Says Committed To Re-engaging With Vista Outdoor; Says Not Withdrawing, And Does Not Intend To Reduce, Its $43 Per Share All-Cash Offer

Sable Offshore Entered Into Subscription Agreements To Issue 7.50M Shares Of Its Common Stock In A Private Placement To Institutional Investors; Company Expects To Receive Gross Proceeds Of Approximately $150M

<p>This firm-fixed price contract is worth up to&nbsp;$99.80 million&nbsp;over five years and simplifies and expedites the ability for services to access the existing capabilities within Maven Smart System. Maven Smart System is part of the National Geospatial-Intelligence Agency&#39;s Maven AI infrastructure.</p>


Contracts

PLTR

Palantir Says Awarded Contract  By DEVCOM Army Research Laboratory Expanding Maven Smart System Access Across Military Services; Firm-fixed Price Contract Is Worth Up To $99.80M

<p>Wedbush  analyst Nick Setyan   maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Outperform and raises the price target from $170 to $200.</p>


Wedbush Maintains Outperform on Darden Restaurants, Raises Price Target to $200

The latest announcement is out from TFF Pharmaceuticals (TFFP). On April 29, 2024, TFF Pharmaceuticals shared an enlightening scientific presentati...

TFF Pharmaceuticals Signals Advancements in Investor Update

TFF Pharmaceuticals announces pricing of $4.8M public offering

TFF Pharmaceuticals GAAP EPS of -$2.40, revenue of $203.27M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>TFF Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tffp-stock-quote/"><strong>TFFP</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>TFF Pharmaceuticals reported earnings per share of -$2.40. This was below the analyst estimate for EPS of -$2.26.</li><li>The company reported revenue of $203,273.</li><li>This was 190.39% better than the analyst estimate for revenue of $70,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/tffp-stock-earnings-tff-pharmaceuticals-for-q1-of-2024/">TFFP Stock Earnings: TFF Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TFFP Stock Earnings: TFF Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024

Analyst Justin Walsh of JonesTrading reiterated a Buy rating on TFF Pharmaceuticals (TFFP – Research Report), reducing the price target to $4.00. J...

Buy Rating Affirmed for TFF Pharmaceuticals Amid Strong Clinical Data and Market Potential

TFF Pharmaceuticals, Cleveland Clinic advance influenza vaccine candidates into preclinical testing

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Bottom-picking stocks to buy is one of the most difficult strategies in trading and investing. It is a direct antithesis to the adage, &ldquo;the trend is your friend, until it bends.&rdquo; While not for the faint of heart, bold investors are rewarded with the potential to be rewarded exponentially for the risk they are taking.&nbsp;</p>



<p>Bottom-picking <em>is</em> risky and not something you should always do as an investor. But if you were to do it, here&rsquo;s are a few ways to <em>mitigate</em> those risks.&nbsp;</p>



<p>For example, you can consider quality companies that are otherwise getting battered by sellers and are trading at their 52-week lows. So, today, I&rsquo;ll show you three stocks doing just that. To get my list, I used the filter below:</p>



<ul><li>Stock trades near its 52-week low,</li>



<li>Minimum buy rating from analysts, and</li>



<li>Earnings and revenue growth in the last fiscal year.</li>
</ul><p>Getting buy-rated stocks means analysts see potential recovery in the future. The revenue growth metrics also indicate that the companies are doing relatively well.&nbsp;</p>



<p>This list represents the &ldquo;best three&rdquo; from the screen. I arranged it based on how far each stock is from its 52-week low, from highest to lowest. </p>



<h2>Microvast Holdings (MVST)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/04/microvast-mvst.png"><img width="300" height="222" src="https://investorplace.com/wp-content/uploads/2024/04/microvast-mvst-300x222.png" alt="A photo of a Microvast Holdings Inc (MVST) sign outside a building."></a><p>The growing demand for EVs has spotlighted companies like <strong>Microvast Holdings </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/mvst-stock-quote/"><strong>MVST</strong></a>). Microvast specializes in advanced battery technology, wherein it builds and develops battery systems used in utility-scale energy storage systems and electric commercial vehicles.&nbsp;</p>



<p>The company has created various proprietary technologies in the entire battery system. Microvast has a solid footprint globally and sells its products in three main regions: North and South America, EMEA, and Asia Pacific.&nbsp;</p>



<p>Microvast reported a <a href="https://ir.microvast.com/news-releases/news-release-details/microvast-reports-2023-financial-results">49.9% YOY revenue increase in FY&rsquo;23.</a> This excellent performance was primarily due to improvements in the EMEA and Asia Pacific regions. Specifically, EMEA is nearly operating at breakeven. Meanwhile, the business in Asia Pacific is entirely self-funding and profitable. The company is hoping for similar results in the Americas shortly.&nbsp;</p>



<p>In other good news, the company&rsquo;s net loss improved from $158.2 million in 2022 to $106.4 million in 2023. Microvast inches towards complete profitability and analysts have plenty of reasons to rate it as a strong buy. The stock is also trading 53.3% higher than its 52-week low. So, if you&rsquo;re looking for stocks to buy, don&rsquo;t miss out on MVST.</p>



<h2>TFF Pharmaceuticals (TFFP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div><p>Biotech is full of baskets of opportunities waiting to be discovered. New firms race to be first to market. <strong>TFF Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tffp-stock-quote/"><strong>TFFP</strong></a>) is one of these contenders. The company develops the commercialization of patented Thin Film Freezing (TFF) by transforming medicine into a potent dry powder for better results.&nbsp;</p>



<p>TFF has two main drug candidates: Voriconazole Inhalation Powder (TFF VORI) and Tacrolimus Inhalation Powder (TFF TAC). Both products use its patented technology and help lung transplant and pulmonary aspergillosis patients.</p>



<p>A quick glance at TFF Pharma&rsquo;s <a href="https://tffpharma.com/press_releases/tff-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results/">FY&rsquo;23 results</a> reported revenues of $733,871, up from $495,805 in 2023. Harlan Weisman, M.D., the company&rsquo;s CEO, says, &ldquo;Over the last several months, we have made significant progress showing that our Thin Film Freezing technology can be successfully applied.&rdquo; Additionally, TFF TAC is heading to another positive catalyst, as the FDA is expected to provide feedback for its <a href="https://tffpharma.com/press_releases/tff-pharmaceuticals-reports-first-quarter-financial-results-and-provides-corporate-update/">Clinical Development Plan in Q2FY&rsquo;24</a>.</p>



<p>Though still operating at a loss, the company managed to minimize net losses to $21.2 million, a noticeable improvement from last year&rsquo;s loss of $31.8 million. The company&rsquo;s excellent prospects and growing financials make a strong case for considering it one of the best bargain stocks to buy.</p>



<p>But if you need something more, you&rsquo;d be happy to know analysts rate TFFP stock as <a href="https://www.nasdaq.com/market-activity/stocks/tffp/analyst-research">a Strong Buy</a>. Additionally, it&rsquo;s trading 25.3% higher from its 52-week low.&nbsp;</p>



<h2>My Size (MYSZ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/growthstocks_1600_02-300x169.jpg" alt="Hand of woman watering small plant in pot shaped like growing graph representing growth stocks. Sleeper Growth Stocks"><div>Source: Khakimullin Aleksandr / Shutterstock</div></div><p>Formerly known as Knowledgetree Ventures, <strong>My Size</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mysz-stock-quote/"><strong>MYSZ</strong></a>) is an eCommerce platform that lets users build their online profile and store their personal measurements, which will allow buyers to make purchases to retailers using their data and get the right fit.&nbsp;</p>



<p>While this may sound simple enough, the company uses a <a href="https://mysizeid.com/reports/naiz-fit-a-my-size-inc-company-unveils-groundbreaking-generative-ai-strategies-to-revolutionize-fashion-tech/">groundbreaking generative AI tool</a> that lets users work with specialized language models to help customers receive tailored product reals that suit their needs. In addition, the company&rsquo;s AI provides virtual try-ons that allow customers to mix and match garments and visually show how pairs work together.&nbsp;</p>



<p>My Size reported improvements in FY&rsquo;23. Revenue hit $7 million, up from $4.5 million last year. Meanwhile, the bottom line ended at a $6.38 million loss compared to last year&rsquo;s $8.31 million loss. Unfortunately, <a href="https://investorplace.com/earning-results/2024/04/mysz-stock-earnings-my-size-for-q4-of-2023/">some financial metrics missed estimates</a> for Q4 and the whole year, and the stock has taken a beating ever since.&nbsp;</p>



<p>Still, MYSZ stock is rated as a <a href="https://www.nasdaq.com/market-activity/stocks/mysz/analyst-research">Strong Buy</a>, trading 7.6% higher than its 52-week low. More adventurous investors looking for stocks to buy might see this as an opportunity.&nbsp;</p>



<p><em>On the date of publication, Rick Orford did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com </em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em>Publishing Guidelines</em></a>.</p>
<div><p>Rick Orford is a Wall Street Journal best-selling author, investor, influencer, and mentor. His work has appeared in the most authoritative publications, including Good Morning America, Washington Post, Yahoo Finance, MSN, Business Insider, NBC, FOX, CBS, and ABC News.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/06/3-52-week-low-losers-ready-to-become-big-time-stock-winners/">3 52-Week-Low Losers Ready to Become Big-Time Stock Winners</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 52-Week-Low Losers Ready to Become Big-Time Stock Winners

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>TFF Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tffp-stock-quote/"><strong>TFFP</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>TFF Pharmaceuticals reported earnings per share of -$1.22. This was above the analyst estimate for EPS of -$1.78.</li><li>The company reported revenue of $650,222.</li><li>This was 766.96% better than the analyst estimate for revenue of $75,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/tffp-stock-earnings-tff-pharmaceuticals-for-q2-of-2024/">TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

TFF Pharmaceuticals GAAP EPS of -$1.22 misses by $0.41, revenue of $0.65M beats by $0.5M

TFF Pharmaceuticals enters pact for dry powder mRNA-based Covid treatment

MVST

MYSZ

Press Releases

General

TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Health Care

TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing

TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Earnings

TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

TFF Pharmaceuticals

TFF Pharmaceuticals (TFFP) Forecast

TFF Pharmaceuticals (NASDAQ:TFFP) Stock, Quote.Headers.trade-ideas